Harnessing T cells to save and improve millions of lives

Genocea discovers and develops vaccines and immunotherapies using a transformational technology platform for T cell antigen discovery.

Cutting edge technologies. Compelling solutions.

Genocea’s proprietary technology platform ATLAS™ is the first of its kind to enable comprehensive profiling of T cell responses between hundreds of humans exposed to a pathogen to identify drivers of T cell response.

Deep pipeline of medicines that matter.

Genocea’s rich pipeline of T cell-enabled product candidates include: GEN-003, a therapy against HSV-2, GEN-004 to prevent pneumococcal diseases, and earlier stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

About Genocea

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen.

Learn more

Disease Focus

Infectious diseases remain an urgent and persistent global health threat, in both the developed and the developing world. Vaccines are recognized as the most cost-effective and successful approach to managing such diseases, yet traditional methods for discovering and developing vaccines are too slow and insufficiently comprehensive to meaningfully address the complexity of many pathogens.

Learn more

  • © 2014 Genocea. All Rights Reserved
  • Site Map